Συναλλαγές Tango Therapeutics Inc - TNGX CFD

Tango Therapeutics Inc. (NASDAQ: TNGX) is an oncology biotech company developing precision cancer therapies based on synthetic lethality—targeting tumor vulnerabilities created by genetic loss. Its lead candidates aim at STK11, PRMT5, and other genetically defined tumor types. Tango combines proprietary CRISPR screening with computational biology to accelerate pipeline advancement. The company provides early-stage, high-science exposure to next-gen targeted cancer treatments.